SG11201605532YA - Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition - Google Patents

Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Info

Publication number
SG11201605532YA
SG11201605532YA SG11201605532YA SG11201605532YA SG11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
castor oil
acid compound
polyoxyethylene castor
containing pharmaceutical
Prior art date
Application number
SG11201605532YA
Other languages
English (en)
Inventor
Yoko Endo
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201605532YA publication Critical patent/SG11201605532YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201605532YA 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition SG11201605532YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10
PCT/JP2015/050333 WO2015105134A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Publications (1)

Publication Number Publication Date
SG11201605532YA true SG11201605532YA (en) 2016-08-30

Family

ID=53523959

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605532YA SG11201605532YA (en) 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Country Status (19)

Country Link
US (3) US20160317512A1 (https=)
EP (2) EP3093021B1 (https=)
JP (5) JP6012775B2 (https=)
KR (6) KR102111157B1 (https=)
CN (2) CN105828817B (https=)
AU (1) AU2015205268B2 (https=)
BR (1) BR112016015911B1 (https=)
CA (1) CA2934612C (https=)
EA (1) EA031723B1 (https=)
ES (2) ES2953346T3 (https=)
GE (2) GEAP201814216A (https=)
IL (1) IL246654B (https=)
MX (1) MX2016009058A (https=)
MY (1) MY166210A (https=)
PH (1) PH12016501327A1 (https=)
SG (1) SG11201605532YA (https=)
TW (1) TWI612960B (https=)
UA (1) UA121744C2 (https=)
WO (1) WO2015105134A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20186917B (en) 2014-01-10 2018-11-12 Pharmaceutical Co Ltd Santen Pharmaceutical preparation including pyridylamino acetic acid compound
BR112016015909B1 (pt) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
ES2953346T3 (es) * 2014-01-10 2023-11-10 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto de ácido piridilaminoacético y aceite de ricino polioxietilenado
EP3320904B1 (en) 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
TWI842679B (zh) 2017-09-29 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥
WO2019124487A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ
CN111526876A (zh) * 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
CN114761022B (zh) * 2019-11-29 2024-02-13 千寿制药株式会社 药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
HUE042839T2 (hu) 2008-03-12 2019-07-29 Ube Industries Piridilaminoecetsav vegyületek
HRP20160104T1 (hr) 2009-03-30 2016-03-25 Ube Industries Farmaceutski pripravak za liječenje ili prevenciju glaukoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
BR112016015909B1 (pt) * 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
ES2953346T3 (es) * 2014-01-10 2023-11-10 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto de ácido piridilaminoacético y aceite de ricino polioxietilenado
GEP20186917B (en) * 2014-01-10 2018-11-12 Pharmaceutical Co Ltd Santen Pharmaceutical preparation including pyridylamino acetic acid compound

Also Published As

Publication number Publication date
TWI612960B (zh) 2018-02-01
AU2015205268B2 (en) 2019-03-14
US20160317512A1 (en) 2016-11-03
EP3888654B1 (en) 2023-06-14
MX2016009058A (es) 2016-09-09
EP3093021A1 (en) 2016-11-16
KR20160100977A (ko) 2016-08-24
PH12016501327B1 (en) 2017-02-06
JP6793172B2 (ja) 2020-12-02
JP7170020B2 (ja) 2022-11-11
JP6012775B2 (ja) 2016-10-25
KR20240096869A (ko) 2024-06-26
CN110251516B (zh) 2022-05-03
KR20220146691A (ko) 2022-11-01
HK1224191A1 (zh) 2017-08-18
JP7546027B2 (ja) 2024-09-05
UA121744C2 (uk) 2020-07-27
IL246654B (en) 2020-05-31
GEAP201814216A (en) 2018-07-25
CA2934612A1 (en) 2015-07-16
KR102111157B1 (ko) 2020-05-14
MY166210A (en) 2018-06-22
JP6449205B2 (ja) 2019-01-09
CN105828817A (zh) 2016-08-03
ES2874547T3 (es) 2021-11-05
EA201691139A1 (ru) 2017-02-28
WO2015105134A1 (ja) 2015-07-16
KR102458180B1 (ko) 2022-10-21
EP3888654A1 (en) 2021-10-06
CA2934612C (en) 2021-09-07
JP2021011508A (ja) 2021-02-04
US20200113880A1 (en) 2020-04-16
NZ721530A (en) 2021-03-26
CN105828817B (zh) 2019-07-05
US20230372316A1 (en) 2023-11-23
EA031723B1 (ru) 2019-02-28
KR102230683B1 (ko) 2021-03-19
EP3093021B1 (en) 2021-06-02
KR20180050770A (ko) 2018-05-15
KR20210032547A (ko) 2021-03-24
KR102675685B1 (ko) 2024-06-14
JP2019034973A (ja) 2019-03-07
JP2015147762A (ja) 2015-08-20
IL246654A0 (en) 2016-08-31
EP3093021A4 (en) 2017-07-26
GEP20186916B (en) 2018-11-12
ES2953346T3 (es) 2023-11-10
KR20200053651A (ko) 2020-05-18
AU2015205268A1 (en) 2016-07-14
BR112016015911A2 (https=) 2017-08-08
JP2022189964A (ja) 2022-12-22
TW201611833A (en) 2016-04-01
BR112016015911B1 (pt) 2022-04-05
PH12016501327A1 (en) 2017-02-06
KR101858373B1 (ko) 2018-05-15
CN110251516A (zh) 2019-09-20
JP2017031177A (ja) 2017-02-09

Similar Documents

Publication Publication Date Title
IL252477A0 (en) 2-aminopyrimidine compound, pharmaceutical structure and its use
IL246654A0 (en) A pyridylamino acetic acid compound and a medical preparation containing polyoxyethylene castor oil
IL253123A0 (en) Preparations for administration through the skin and their uses
IL246186A0 (en) Pharmaceutical preparations containing azd9291
EP3102200A4 (en) Therapeutic compounds and compositions
IL246447B (en) A pharmaceutical preparation containing a pyridylaminoacetic acid compound
EP3102585A4 (en) Boronic acid esters and pharmaceutical formulations thereof
IL246655B (en) A medical preparation containing a pyridyl amino acetic acid compound
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
EP3139741A4 (en) Methods and compositions comprising 10-hydroxy-2-decenoic acid
EP3149099A4 (en) Synthetic acid compositions and uses thereof
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
ZA201703976B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
ZA201703398B (en) Pharmaceutical composition and methods
IL250729A0 (en) A pyrazolothiazole compound and a drug containing it
PL3184492T3 (pl) Preparat antyseptyczny
GB201417589D0 (en) Pharmaceutical Formulations
AP2017009706A0 (en) Pharmaceutical compound comprising 13 glycerides, formulation and application thereof
HK1234280A1 (en) Methods and compositions comprising 10-hydroxy-2-decenoic acid
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same
HK1232137B (en) Therapeutic compounds and compositions